Cited by 25Substance Abuse Treatment and OutcomesOpioid Use Disorder TreatmentSynthesis and pharmacology of benzodiazepine derivatives

Benzodiazepine dependence

Ashton, Heather·2004·Adverse Syndromes and Psychiatric Drugs

Integrity signals

Registry

Crossref · 10.1093/med/9780198527480.003.0013

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The disproportionately large occupancy change at low diazepam doses is consistent with the clinical observation of increasing withdrawal severity near zero.

    “At low doses, small reductions have disproportionately large effects; for example, 5 to 0 mg changes occupancy by 16.8 p.p., exceeding the change from 100 to 50 mg (13.3 p.p.), consistent with the clinical observation of increasing withdrawal severity near zero (Ashton, 2004).”
  • A 1 mg reduction is generally tolerable from 20 mg diazepam but not from 5 mg, where smaller decrements are preferred.

    “For example, it has been observed that 1 mg reductions are generally tolerable from 20 mg diazepam but not from 5 mg, where smaller decrements are preferred (Ashton, 2004), suggesting a hyperbolic relationship between dose reduction and withdrawal severity.”
  • Withdrawal symptoms are hyperbolically dose-dependent: larger reductions cause greater severity, particularly at lower doses.

    “Withdrawal symptoms also appear to be hyperbolically dose-dependent: larger reductions cause greater severity, particularly at lower doses (Ashton, 2004).”
  • A 5 to 0 mg diazepam reduction changes GABA-A occupancy by 16.8 percentage points, exceeding the change from 100 to 50 mg (13.3 p.p.).

    “At low doses, small reductions have disproportionately large effects; for example, 5 to 0 mg changes occupancy by 16.8 p.p., exceeding the change from 100 to 50 mg (13.3 p.p.), consistent with the clinical observation of increasing withdrawal severity near zero (Ashton, 2004).”

Cited by

Sorted by citations

Authors
Ashton, H.
Corresponding author
Ashton, Heather
Venue
Adverse Syndromes and Psychiatric Drugs
Published
2004-05
Pages
239-260
OpenAlex
W4252235324
Cited by
25
References
0
Citations by year
2026: 1 · 2024: 2 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 1 · 2013: 1 · 2012: 1
FWCI
5.72
Type
book chapter
Language
en
Open access
closed
Locations
Oxford University Press eBooks (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
Keywords
benzodiazepine dependence, benzodiazepines, substance use disorders, drug addiction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review